Multiple sclerosis drug pulled from market after reports of brain inflammation


Pharmaceutical companies which manufacture the multiple sclerosis drug, Zinbryta, have stopped production and clinical trials, following reports of brain inflammation. As of now, Zinbryta has been prescribed to over 8,000 people, but due to the aggressive nature of encephalitis, doctors were quick to recall the drug.

For full article, click here


Samantha Underwood

Comments are closed.

Skip to toolbar